Search Results Search Sort by RelevanceMost Recent Policy Forum May 2022 What Should Dietary Supplement Oversight Look Like in the US? Elizabeth Richardson, MSc, Farzana Akkas, MSc, and Amy B. Cadwallader, PhD Statutory limitations prevent the FDA from effectively regulating dietary supplements and have generated numerous calls for reform. AMA J Ethics. 2022;24(5):E402-409. doi: 10.1001/amajethics.2022.402. Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410. Policy Forum Mar 2023 What Should Be Clinicians’ Roles in Regulatory Assessment of Prospective Interventions’ Risks of Exacerbating Inequity? Anushka Bhaskar and Daniel Carpenter, PhD When regulatory decisions express overconfidence, one risk is that the costliness or misinformation will exacerbate health inequity. AMA J Ethics. 2023;25(3):E204-209. doi: 10.1001/amajethics.2023.204. Policy Forum Nov 2022 If Patients Don’t Use Available Health Service Pricing Information, Is Transparency Still Important? Christopher Whaley, PhD and Austin Frakt, PhD Online tools intended to make health care purchasing resemble “consumerism” have had little effect on improving transparency for patients. AMA J Ethics. 2022;24(11):E1056-1062. doi: 10.1001/amajethics.2022.1056. Policy Forum Nov 2022 Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm Kevin Schulman, MD and Barak Richman, PhD, JD Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions. AMA J Ethics. 2022;24(11):E1063-1068. doi: 10.1001/amajethics.2022.1063. Policy Forum Nov 2016 Affirmative and Responsible Health Care for People with Nonconforming Gender Identities and Expressions Kristen L. Eckstrand, MD, PhD, Henry Ng, MD, MPH, and Jennifer Potter, MD Physicians should extend gender-affirming treatment to gender-nonconforming people, who experience discrimination and health disparities. AMA J Ethics. 2016;18(11):1107-1118. doi: 10.1001/journalofethics.2016.18.11.pfor1-1611. Policy Forum Aug 2010 Addressing Gay Men’s Health: The Script Needs a Rewrite Jim Pickett An argument for replacing the disease-centered approach to gay men’s health with a whole-person, wellness approach. Virtual Mentor. 2010;12(8):668-672. doi: 10.1001/virtualmentor.2010.12.8.pfor2-1008. Policy Forum Aug 2010 Repealing Don’t Ask, Don’t Tell: A Step Forward in Patient-Physician Trust Frederick Nagel, MD “Don’t Ask, Don’t Tell” has infringed on the trust between patient and physician. When it is repealed, physicians will have to invite confidences from patients who have long been unable to give them. Virtual Mentor. 2010;12(8):663-667. doi: 10.1001/virtualmentor.2010.12.8.pfor1-1008.
Policy Forum May 2022 What Should Dietary Supplement Oversight Look Like in the US? Elizabeth Richardson, MSc, Farzana Akkas, MSc, and Amy B. Cadwallader, PhD Statutory limitations prevent the FDA from effectively regulating dietary supplements and have generated numerous calls for reform. AMA J Ethics. 2022;24(5):E402-409. doi: 10.1001/amajethics.2022.402.
Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410.
Policy Forum Mar 2023 What Should Be Clinicians’ Roles in Regulatory Assessment of Prospective Interventions’ Risks of Exacerbating Inequity? Anushka Bhaskar and Daniel Carpenter, PhD When regulatory decisions express overconfidence, one risk is that the costliness or misinformation will exacerbate health inequity. AMA J Ethics. 2023;25(3):E204-209. doi: 10.1001/amajethics.2023.204.
Policy Forum Nov 2022 If Patients Don’t Use Available Health Service Pricing Information, Is Transparency Still Important? Christopher Whaley, PhD and Austin Frakt, PhD Online tools intended to make health care purchasing resemble “consumerism” have had little effect on improving transparency for patients. AMA J Ethics. 2022;24(11):E1056-1062. doi: 10.1001/amajethics.2022.1056.
Policy Forum Nov 2022 Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm Kevin Schulman, MD and Barak Richman, PhD, JD Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions. AMA J Ethics. 2022;24(11):E1063-1068. doi: 10.1001/amajethics.2022.1063.
Policy Forum Nov 2016 Affirmative and Responsible Health Care for People with Nonconforming Gender Identities and Expressions Kristen L. Eckstrand, MD, PhD, Henry Ng, MD, MPH, and Jennifer Potter, MD Physicians should extend gender-affirming treatment to gender-nonconforming people, who experience discrimination and health disparities. AMA J Ethics. 2016;18(11):1107-1118. doi: 10.1001/journalofethics.2016.18.11.pfor1-1611.
Policy Forum Aug 2010 Addressing Gay Men’s Health: The Script Needs a Rewrite Jim Pickett An argument for replacing the disease-centered approach to gay men’s health with a whole-person, wellness approach. Virtual Mentor. 2010;12(8):668-672. doi: 10.1001/virtualmentor.2010.12.8.pfor2-1008.
Policy Forum Aug 2010 Repealing Don’t Ask, Don’t Tell: A Step Forward in Patient-Physician Trust Frederick Nagel, MD “Don’t Ask, Don’t Tell” has infringed on the trust between patient and physician. When it is repealed, physicians will have to invite confidences from patients who have long been unable to give them. Virtual Mentor. 2010;12(8):663-667. doi: 10.1001/virtualmentor.2010.12.8.pfor1-1008.